Volume : 09, Issue : 10, October – 2022



Authors :

Jayesh M. Rajput

Abstract :

Rabeprazole Sodium belongs to a class of Anti-Secretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, used to prevent production of acid in the stomach, it reduces symptoms and prevents injury to the oesophagus or stomach in patients with gastroesophageal reflux disease (GERD). It has a daily dose of 10 mg minimum and 20 mg maximum. In this formulation Rabeprazole Sodium is used as an active pharmaceutical ingredient (API), and excipients such as Sodium Alginate, Guar Gum, Sodium Bicarbonate, Calcium Carbonate, Methyl Paraben, Propyl Paraben are used. In this study FTIR was done for evaluation of pure drug and to evaluate between the API and excipients, all the results were within its standard ranges. Many tests such as In-Vitro gelation time/Floating lag time, Floating time, Raft weight, Raft volume, Content uniformity, Viscosity of suspension and raft, Micromeritic study and In-Vitro drug release study was conducted and all the obtained results were within the standard ranges. Formulation SA3 and GG5 due to their linear drug release they were selected for Stability Study. 2 Months Stability Study were conducted and on each 1-Month interval readings were taken, no major difference in formulation and readings were observed after 3rd month study But, Further Long-Term stability study and In-Vivo study was recommended.
Keywords: Rabeprazole Sodium, Oesophagitis, Gerd, Gastroesophageal Reflux Disorder, Raft-Forming Suspension

Cite This Article:

Please cite this article in Jayesh M. Rajput, Formulation, Optimization And Evaluation Of In-Situ Raft-Forming Suspension Of Rabeprazole Sodium Using Guar Gum., Indo Am. J. P. Sci, 2022; 09(10).

Number of Downloads : 10


1) Y. W. Chien, “Novel Drug delivery system”, 2nd Edition, Informa Healthcare, pp- 139-196.
2) S.T. Carter, “Dispensing for Pharmaceutical Student”, CBS Publication, pp-3-7.
3) A Pawar and R. S. Gaud, “Modern Dispensing Pharmacy”, 3rd Edition, Career Publication, pp-375-378.
4) N. K. Jain, “Advances in Control and Novel Drug delivery system”, CBS Publication, pp-235-240.
5) L. Shargel, A. H. Mutnick, P. F. Souney and L. N. Swanson, “Comprehensive Pharmacy Review”, South Asian, 7th Edition, pp-151-163.
6) D. T. Baviskar and D. K. Jain, “Novel drug delivery system”, Nirali Prakashan, pp-1.1-1.10.
7) W. J. Bulsiewiez and R. D. Madanick, “Anti-Reflux surgery in the proton pump inhibitor era”, cleavel and clinic journal of medicine, 2012, Volume-79(4), pp-273-281.
8) Y. K. Wang, W. H. Hsu, S. S. W. Wang, et.al, “Current Pharmacological management of Gastro-Oesophageal Reflux disease”, Gastroenterology research and practice, 2013, Article id-983653, Hindawi publishing corporation, pp-1-12.
9) S. C. Nwokediuko, “Current trends in the management of gastro-oesophageal reflux disease-A Review”, International Scholarly research Network, 2012, Article id-391631, pp-1-11.
10) https://www.aafp.org/afp/2008/0815/p483.html
11) A. Pandey, G. Kumar, P. Kothiyal and Y. Barshiliya, “A Review on current approaches in gastro retentive drug delivery system”, Asian Journal of Pharmacy and Medical Science, Volume-2(4), 2012, pp-60-70.
12) S. Kumar, F. Jamil, Rajput and S. Sharma, “Gastro Retentive drug delivery system: features and facts”, International Journal of research in pharmaceutical and biomedical sciences, 2012, Volume-3(1): pp-125-136.
13) R. C. Rowe, P. J. Sheskey and M. N. Quinn, “Handbook of Pharmaceutical excipients”, 6th Edition pharmaceutical press publication, pp-110, 159, 298, 478, 622 and 782.
14) J. M. Babu, G. M. Reddy, B. V. Bhaskar, et.al, “Identification and Characterization of potential impurities of Rabeprazole Sodium”, Journal of Pharmaceutical and Biomedical Analysis, 43(2007), pp-1262-1269.
15) B. J. Lee, S. Ren, M. J. Park and H. Sah, “Effect of pharmaceutical excipients on aqueous stability of Rabeprazole Sodium”, International Journal of Pharmaceutics, 2008, 350: pp-197-204.
16) N. V. S. Ramakrishna, K. N. Vishwotta, S. Wishu, et.al. “High-Performance liquid chromatography method for the quantification of Rabeprazole in human plasma using solid-phase extraction”, Journal of Chromatography, 2005, 816: pp-209-214.
17) K.A. Fostera, M. Morgen B, B. Murrib, Yatesh, R. M. Fanchera, J. Ethrmanne, O.S. Gudmundssona and M. J. Hageman, “Utility of In-Situ sodium alginate/Karaya gum gels to facilitate gastric retention in rodents”, International Journal of Pharmaceutics, 2012, 434: pp-406-412.
18) K. A. Erk, B. M. Elliott, K. E. Steckbeck and L.R. Murray, “Rheological investigation of the shear strength, durability and recovery of alginate rafts formed by antacid medication in varying pH environments”, International Journal of Pharmaceutics, 2013, 457: pp-118-123.
19) Y. Kinoshita, M. Hirayama, S. Hamada, et.al., “Efficacy of Rabeprazole in patients with reflux Esophagitis, A Single-Center, open-label, practice-based, post-marketing surveillance investigation, December-2002, Volume 63, no-12: pp-810-820.